NEOG vs CBLL vs LNTH Stock Comparison

Neogen, Ceribell and Lantheus Holdings Prices as of Oct 27, 2026 Peers: Industry group
NEOG Neogen Corp
$12.47 -9.4% 1M +100.8% 1Y
Market cap
$2.72B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
CBLL Ceribell, Inc.
$27.22 +14.9% 1M +111.2% 1Y
Market cap
$1.04B
P/E
–
Revenue (TTM)
$101.96M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins
LNTH Lantheus Holdings, Inc.
$100.15 +0.4% 1M +72.3% 1Y
Market cap
$6.54B
P/E
23.7x
Revenue (TTM)
$1.56B
Div. yield
–
Diagnostic Equipment Healthcare
8 wins

Head to Head

10 decided of 12

Lantheus Holdings leads on 8 of the 12 questions below (Lantheus Holdings 8, Ceribell 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNEOGCBLLLNTHLeader
Larger companyMarket capitalisation $2.72B $1.04B $6.54B LNTH
Cheaper on earningsLower P/E, profitable companies only -48.5x -15.7x 23.7x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 39.0x — 17.4x LNTH
Faster revenue growthRevenue growth, trailing twelve months -0.3% +31.7% +2.3% CBLL
More profitableNet margin, trailing twelve months -6.3% -64.7% 17.7% LNTH
Better return on capitalReturn on invested capital -0.2% — 12.5% LNTH
Less leveragedLower net debt / EBITDA 5.4x 1.6x -0.1x LNTH
Higher dividend yieldTrailing dividend yield — — — –
Better 1-year returnPrice return, last 12 months +100.8% +111.2% +72.3% CBLL
Better 5-year returnAnnualised price return, 5 years -21.4%/yr — +34.4%/yr LNTH
Less volatileAnnualised volatility, 1 year 55.6% 52.1% 32.3% LNTH
Higher overall scoreMean of the five percentile scores vs peers 58/100 38/100 80/100 LNTH

Percentile Scorecard

NEOGCBLLLNTH

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNEOGCBLLLNTH
Valuation 71 #66 of 227 22 #178 of 227 80 #46 of 227
Growth 50 #110 of 219 22 #172 of 219 63 #82 of 219
Profitability 62 #79 of 206 38 #129 of 206 94 #13 of 206
Financial Health 46 #128 of 238 81 #46 of 238 69 #74 of 238
Shareholder Returns 58 #57 of 134 30 #94 of 134 93 #11 of 134
Overall 58 38 80
  • NEOG ranked among 247 companies in Medical Devices and Diagnostics
  • CBLL ranked among 247 companies in Medical Devices and Diagnostics
  • LNTH ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNEOGCBLLLNTHSPY
1 month -9.4%+14.9%+0.4% -0.2%
3 months +35.7%+52.7%-2.4% +3.9%
6 months +33.5%+30.9%+19.9% +8.2%
Year to date +78.4%+24.1%+50.5% +12.9%
1 year +100.8%+111.2%+72.3% +12.3%
3 years -18.6%—+49.9% +87.4%
3 years, per year -6.6%—+14.4% +23.3%
5 years -69.9%—+337.5% +67.9%
5 years, per year -21.4%—+34.4% +10.9%
10 years -35.8%—+1,092.3% +261.1%
10 years, per year -4.3%—+28.1% +13.7%

Risk

MeasureNEOGCBLLLNTHSPY
Volatility, 1Y 55.6%52.1%32.3% 12.7%
Downside volatility, 1Y 46.5%49.5%27.5% 12.7%
Beta vs S&P 500, 1Y 1.451.210.59 1.00
Return / volatility, 1Y 1.812.132.24 0.97
Max drawdown, 5Y -90.6%-63.9%-59.5% -25.4%
From 52-week high -10.8%-1.7%-9.7% -1.2%
52-week high $13.98$27.68$110.94 $779.14
52-week low $5.41$10.92$50.69 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNEOGCBLLLNTH
P/E now vs peer median -48.5xmedian 29.6x -15.7xmedian 29.6x 23.7xmedian 29.6x
P/S now vs peer median 3.1xmedian 2.9x 10.2xmedian 2.9x 4.2xmedian 2.9x
EV/EBITDA now vs peer median 30.0xmedian 17.4x -13.6xmedian 17.4x 16.5xmedian 17.4x
P/FCF now vs peer median 54.7xmedian 22.3x -19.0xmedian 22.3x 16.9xmedian 22.3x
P/B now vs peer median 1.3xmedian 2.3x 8.1xmedian 2.3x 5.0xmedian 2.3x
PEG now vs peer median 1.73median 1.04 —median 1.04 0.22median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNEOGCBLLLNTH
Revenue $883.99M $101.96M $1.56B
Gross profit $418.98M $90.65M $936.02M
Operating income -$7.38M -$69.97M $302.34M
Net income -$56.10M -$66.00M $275.31M
Free cash flow $49.80M -$54.72M $387.83M
R&D $19.76M $22.95M $173.09M
EPS (diluted) $-0.26 $-1.74 $4.08
Cash & equivalents $172.00M $32.66M $593.30M
Total debt $774.20M $19.98M $571.05M
Shares (diluted) 218.10M 38.03M 67.52M
Enterprise value $2.06B $442.19M $4.70B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNEOGCBLLLNTH
P/E -48.5x -15.7x 23.7x
P/FCF 54.7x -19.0x 16.9x
P/Operating cash flow 31.9x -19.3x 15.8x
P/S 3.1x 10.2x 4.2x
P/B 1.3x 8.1x 5.0x
P/Tangible book 3.4x 8.1x 10.5x
EV/EBITDA 30.0x -13.6x 16.5x
EV/EBIT -450.7x -13.3x 21.5x
EV/Revenue 3.8x 9.1x 4.2x
EV/FCF 66.8x -17.0x 16.8x
EV/Operating cash flow 39.0x -17.2x 15.8x
PEG (3Y EPS CAGR) 1.73 – 0.22

Growth

14 metrics
MetricNEOGCBLLLNTH
Revenue growth (1Y) -0.3% 31.7% 2.3%
Revenue CAGR (3Y) -1.3% – 11.4%
Gross profit growth (1Y) 1.8% 33.4% -3.4%
Gross profit CAGR (3Y) -3.1% – 16.3%
Operating income growth (1Y) 99.3% -34.6% -30.9%
Operating income CAGR (3Y) -29.0% – 118.8%
Net income growth (1Y) 94.6% -33.6% 1.6%
Net income CAGR (3Y) -28.3% – 102.1%
EPS growth (1Y) 94.6% -27.5% 5.8%
EPS CAGR (3Y) -28.0% – 105.5%
Operating cash flow growth (1Y) -1.9% -44.3% -21.7%
Operating cash flow CAGR (3Y) 2.9% – 14.5%
Free cash flow growth (1Y) 1,631% -41.8% -10.1%
Free cash flow CAGR (3Y) 126.1% – 103.0%

Profitability

14 metrics
MetricNEOGCBLLLNTH
Gross margin 47.4% 88.9% 60.1%
EBITDA margin 12.5% -67.1% 25.4%
Operating margin -0.8% -68.6% 19.4%
Pretax margin -7.7% -64.7% 23.3%
Net margin -6.3% -64.7% 17.7%
FCF margin 5.6% -53.7% 24.9%
Operating cash flow margin 9.6% -53.0% 26.5%
Return on equity -2.7% -49.0% 21.8%
Return on assets -1.7% -38.3% 11.6%
Return on invested capital -0.2% – 12.5%
Return on capital employed -0.2% -45.1% 14.8%
Asset turnover 0.3x 0.6x 0.7x
Cash conversion (OCF / net income) -1.5x 0.8x 1.5x
Stock comp / revenue 1.3% 16.1% 5.0%

Financial Health

11 metrics
MetricNEOGCBLLLNTH
Debt / assets 23.4% 12.0% 23.6%
Debt / equity 0.4x 0.2x 0.4x
Net debt / EBITDA 5.4x 1.6x -0.1x
Debt / FCF 15.5x -0.4x 1.5x
Liabilities / assets 36.8% 22.9% 45.7%
Equity / assets 63.2% 77.1% 54.3%
Interest coverage – -38.6x 15.3x
Current ratio 3.9x 9.2x 3.1x
Quick ratio 2.1x 8.6x 2.8x
Cash ratio 1.2x 7.5x 1.8x
Altman Z-score 1.52 14.47 5.46

Shareholder Returns

7 metrics
MetricNEOGCBLLLNTH
Dividend yield – – –
Net buyback yield -0.1% -0.6% 2.9%
Shareholder yield -0.1% -0.6% 2.9%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNEOGCBLLLNTH
Forward P/E 39.0xFY2026 – 17.4xFY2026
EPS, next fiscal year $0.32FY2026 $-1.86FY2026 $5.76FY2026
EPS growth, next FY 0.0%FY2026 – -5.3%FY2026
EPS growth, the year after +31.3% – +4.2%
Revenue, next fiscal year $847.28MFY2026 $118.32MFY2026 $1.57BFY2026
Revenue growth, next FY -2.7%FY2026 +32.9%FY2026 +1.8%FY2026
Revenue growth, the year after -1.5% +21.1% +12.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNEOGCBLLLNTH
Held by institutions 100.0% 79.9% 100.0%
Institutions holding 315 124 465
Change in shares held, QoQ +1.6% +2.2% +3.4%
Institutions buying 151 74 248
Institutions selling 106 36 142
Buyers to sellers 1.42 2.06 1.75

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NEOGCBLLLNTH
NEOG 1.00 0.25 0.08
CBLL 0.25 1.00 0.21
LNTH 0.08 0.21 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NEOG, CBLL and LNTH?

Lantheus Holdings (LNTH) is the largest by market capitalisation: Neogen (NEOG) $2.72B, Ceribell (CBLL) $1.04B, Lantheus Holdings (LNTH) $6.54B.

Which company is growing faster?

Ceribell (CBLL) grew revenue fastest over the trailing twelve months: Neogen (NEOG) -0.3%, Ceribell (CBLL) +31.7%, Lantheus Holdings (LNTH) +2.3%.

Which company is more profitable?

Lantheus Holdings (LNTH) has the highest net margin (Neogen (NEOG) -6.3%, Ceribell (CBLL) -64.7%, Lantheus Holdings (LNTH) 17.7%). On return on invested capital, Lantheus Holdings (LNTH) leads (Neogen (NEOG) -0.2%, Lantheus Holdings (LNTH) 12.5%).

Which stock has performed better?

Over the past year Ceribell (CBLL) returned the most: Neogen (NEOG) +100.8%, Ceribell (CBLL) +111.2%, Lantheus Holdings (LNTH) +72.3%. Over five years, Lantheus Holdings (LNTH) compounded fastest (Neogen (NEOG) -21.4%/yr, Lantheus Holdings (LNTH) +34.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Lantheus Holdings (LNTH) has been the steadiest (Neogen (NEOG) 55.6%, Ceribell (CBLL) 52.1%, Lantheus Holdings (LNTH) 32.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NEOG, CBLL and LNTH?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Lantheus Holdings (LNTH) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.